Total: $202.61M | ||||
Company |
Type Of |
Number Of Shares, Units Or Warrants | Amount |
Investors; Placement Agents; Details (Date)@ |
| | ||||
Alizyme plc |
Private placement and open offer |
32.8S |
£32.8 (US$56) |
The open offer consisted of 30.5 shares; Quintiles Transnational Corp. purchased 2.3M shares in a private placement (5/16) |
Altachem |
Private placement of stock and warrants |
4.2S and 2.1W |
C$1.05 (US$0.84) |
Altachem closed the second tranche of a financing that totaled C$1.49M; the shares sold at C$0.25 each, and the one-year warrants are exercisable at C$0.45 per share (5/10) |
Amarin Corp.plc |
Private placement of stock |
13.7S |
$17.8 |
Amarin sold American depository shares in a registered direct offering; 3.5M of the shares were purchased by company directors and officers; Leerink Swann & Co. was placement agent (5/25) |
AspenBio Inc. |
Private placement of stock and warrants |
3.51S and 3.51W |
$3.07 |
Warrants issued in the deal are exercisable for five years at $1.35 per share (5/6) |
Australian |
Rights issue |
43.8S |
A$5.7 (US$4.3) |
The shares were sold at A$0.13 each in a rights issue that was fully underwritten by BBY Ltd.; the company also changed its name to Avantogen Ltd. (5/17) |
Cellegy |
Private placement of stock and warrants |
3.636S and 0.545W |
$6 |
SJ Investments LLC, Tisch Family Interests, Kingsway LLC, Greenway Capital and Kingsbridge Capital Ltd. invested in the financing; the shares were sold at $1.65 each; half the five-year warrants are exercisable at $2.25 per share, and half at $2.50; C.E. Unterberg, Towbin was placement agent (5/13) |
Corgenix |
Private placement of convertible notes and warrants |
N/A and 7.7W |
$3.42 | The convertible notes are due in 2008; investors included Truk International Fund LP, Truk Opportunity Fund LLC and DCOFI Master LDC; they have a nine-month option to invest a further $1.5M; the warrants are convertible into stock at $0.25 per share (5/23) |
Dyax Corp. |
Private placement of stock |
6.315S |
$25.26 | The shares were sold from a shelf registration at $4 each; Deutsche Bank Securities Inc. and SG Cowen & Co. LLC were placement agents (5/19) |
GlycoGenesys |
Private placement of convertible stock and warrants |
N/A |
$4.5 |
The $4.5M is the second tranche of a financing; the first $2M was raised in March; the company sold 4,500 shares of convertible, redeemable Series D preferred stock, currently convertible into 4.5M shares of common stock, and warrants to purchase 4.5M shares at $1.23 each (5/23) |
Hybridon |
Private placement of convertible notes |
N/A |
$5 |
The 4% notes due 2008 initially are convertible into common stock at $0.89 per share (5/20) |
InSite Vision |
Private placement of stock and warrants |
16.4S and 4.9W |
$9 |
The shares were sold at $0.55 each; the five-year warrants are exercisable at $0.6325 per share; Paramount BioCapital Inc. was placement agent (5/9) |
MacroPore |
Private placement of stock and warrants |
1.1S and 2.2W |
$11 |
The shares were sold at $10 each; the investor has an option to purchase 2.2M shares at $10 each until Dec. 31, 2006 (5/2) |
Millenia Hope |
Private placement of stock |
ND |
$0.6 |
The investment completes the first stage of an anticipated much larger private placement being arranged by Private Consulting Group Inc. (5/10) |
Miravant |
Private placement of stock and warrants |
ND |
$8 |
Scorpion Capital Partners LP led the financing, which entailed the sale of preferred stock convertible into common stock at $1 per share; the same number of warrants also are convertible at $1 per share (5/4) |
NexMed Inc. |
Private placement of convertible stock and warrants |
N/A and 1.19W |
$4.45 |
445 shares of preferred stock were sold at $10,000 per share and initially are convertible into common stock at $1.36 per share; NexMed has certain quarterly rights to convert the stock at a 4.5% discount to the price at the time; the four-year warrants are exercisable at $1.43 per share (5/18) |
NovaDel |
Private placement of stock and warrants |
6.7S and 2.4W |
$7 |
The financing was led by ProQuest Investments and included the Caisse de depot et placement du Quebec and others; the five-year warrants are exercisable at $1.30 per share (5/27) |
Oragenics Inc. |
Private placement of stock |
N/A |
$9 |
Fusion Capital Fund II LLC agreed to purchase up to $9M in stock over 30 months, at times and amounts to be determined by Oragenics; the company has an option for another $9M investment following completion of the initial funding (5/24) |
Phytopharm plc (UK; LSE:PYM) |
Private placement and open offer |
8.08S |
£10.1 (US$18.9) |
Canaccord Capital Ltd. underwrote the placement and open offer; shares were issued at £1.25 each (5/4) |
Protalex |
Private placement of stock and warrants |
2.6S and 0.787W |
$5.1 |
The shares were placed at $1.95 each; terms of the warrants were not disclosed; the financing was led by vSpring Capital (5/31) |
Senesco |
Private placement of stock and warrants |
1.6S and 0.798W |
$3.37 |
Warrants issued in the deal are exercisable at $3.38 per share; Oppenheimer & Co. Inc. was placement agent (5/4) |
| | ||||
Notes: | ||||
This chart does not include real estate or manufacturing plant financings. | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
Currency conversions are based on exchange rates at the time of the deal. | ||||
N/A = Not applicable; ND = Not disclosed. | ||||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CDNX = Canadian Venture Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board. | ||||
